AOD-9604 is a modified fragment of human growth hormone designed specifically for fat loss. Here is what the research shows, how it works, dosage protocols, and how it compares to full GH therapy.
Growth hormone's fat-burning properties have been known for decades. The problem is that accessing those properties through direct GH administration comes with a package of side effects — insulin resistance, fluid retention, elevated IGF-1, and the cardiovascular concerns that accompany supraphysiological GH levels — that make it impractical for most people seeking fat loss specifically.
AOD-9604 was developed to solve exactly that problem. It is a modified fragment of the human growth hormone molecule, engineered to retain the lipolytic activity of GH while eliminating its effects on insulin, IGF-1, and cell growth. In principle, it is the fat-burning mechanism of growth hormone isolated and delivered without the metabolic baggage.
The clinical story of AOD-9604 is more complicated — and more instructive — than most peptide research narratives. It reached Phase 3 human trials for obesity treatment. Those trials ultimately did not succeed in demonstrating the efficacy that would support FDA approval. Understanding why requires a closer look at what the research actually showed — and what it did not.
⚠️ Important Disclaimer: AOD-9604 is an investigational research peptide. It is not approved by the FDA or any regulatory agency for human therapeutic use, despite having advanced to Phase 3 clinical trials for obesity. This article is for educational purposes only and does not constitute medical advice.
What Is AOD-9604?
AOD-9604 — where AOD stands for Anti-Obesity Drug — is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone, specifically amino acids 177–191 of the hGH sequence, with a tyrosine residue added at the N-terminus (position 177) to stabilize the fragment.
It was developed by Monash University in Australia in the 1990s, with subsequent clinical development led by the Australian biotechnology company Metabolic Pharmaceuticals. The design rationale was based on the established understanding that the lipolytic activity of GH is mediated primarily by this specific C-terminal region of the molecule — separate from the N-terminal region responsible for GH's anabolic, IGF-1-stimulating, and insulin-antagonizing effects.
By isolating and synthesizing only this fragment, the researchers aimed to capture the fat-burning signal of GH while leaving behind the metabolic side effects that make full GH administration problematic for weight management purposes.
How Does AOD-9604 Work?
AOD-9604's mechanism centers on two complementary fat metabolism pathways:
1. Lipolysis Stimulation
AOD-9604 stimulates lipolysis — the breakdown of stored triglycerides in adipocytes (fat cells) into free fatty acids that can be oxidized for energy. This mirrors one of the core metabolic actions of full GH in fat tissue. The peptide appears to activate this pathway through beta-3 adrenergic receptor-like signaling in adipose tissue, promoting fat mobilization without requiring systemic GH elevation.
2. Lipogenesis Inhibition
Beyond stimulating fat breakdown, AOD-9604 also inhibits lipogenesis — the process by which the body converts excess dietary calories into new fat deposits. This dual action — more fat burned, less fat stored — is what made AOD-9604 attractive as an anti-obesity candidate from a mechanistic standpoint.
What It Does NOT Do
This is equally important to understand. Unlike full-length growth hormone administration:
- AOD-9604 does not stimulate IGF-1 production
- AOD-9604 does not cause insulin resistance or raise fasting glucose
- AOD-9604 does not promote cell proliferation or tissue growth
- AOD-9604 does not affect the pituitary-GH axis or suppress endogenous GH secretion
This selective activity profile is what drove its development as a potential obesity drug — the metabolic benefits without the hormonal consequences.
What the Research Actually Shows
AOD-9604 has a more nuanced research history than most research peptides. Its trajectory from promising preclinical results through clinical development — and the reasons its Phase 3 trials ultimately did not produce approvable results — is important context for anyone evaluating it.
Animal Studies: Consistently Positive
Preclinical research in obese rodent models consistently demonstrated:
- Significant reductions in body fat percentage with AOD-9604 administration
- No effects on blood glucose, insulin levels, or IGF-1
- No effects on bone growth or linear growth in young animals
- Reduction in food intake in some models (suggesting possible central appetite effects beyond peripheral fat metabolism)
(View related animal studies on PubMed)
Human Phase 2 Trials: Modest but Present Signal
Phase 2 trials in overweight and obese adults showed that AOD-9604 produced statistically significant weight loss compared to placebo at certain doses, with a favorable safety profile. Doses of 1 mg/day orally produced the most consistent signal in the Phase 2 program. (View related clinical studies on PubMed)
Phase 3 Trials: The Disappointing Outcome
The Phase 3 PROOF trial — a large, randomized, placebo-controlled trial — did not demonstrate statistically significant superiority of AOD-9604 over placebo for weight loss at the primary endpoint. The effect size seen in Phase 2 did not replicate at the scale and rigor of Phase 3, and Metabolic Pharmaceuticals ultimately discontinued the obesity drug development program.
This is a pattern seen in obesity pharmacotherapy research more broadly — Phase 2 signals frequently do not survive the statistical scrutiny of larger Phase 3 trials. It does not mean AOD-9604 has no biological activity; it means the activity was not large enough to meet the regulatory bar for an approvable obesity drug in a large, diverse population.
GRAS Designation and Food Ingredient Status
In a notable regulatory development, AOD-9604 received Generally Recognized As Safe (GRAS) designation from the FDA in 2014 for use as a food ingredient — a designation that reflects its favorable safety profile even if its efficacy as a weight loss drug was not confirmed at the required magnitude. This GRAS status is frequently cited in the peptide research community and is accurate, though it should not be misread as FDA approval for therapeutic use.
AOD-9604 in the Research Peptide Community: Current Use Context
Despite the Phase 3 setback, AOD-9604 continues to be used in research peptide protocols — primarily because:
- Its mechanism is biologically sound and the fat-specific activity is well-documented in animal research
- Its safety profile is exceptionally clean — no IGF-1 elevation, no glucose effects, no hormonal interference
- It has a GRAS designation reflecting its benign toxicological profile
- It is used in combination with other peptides rather than as a standalone fat loss agent — a context in which its modest individual contribution may be meaningful as part of a stack
The honest framing is this: AOD-9604 probably does have some fat-mobilizing biological activity in humans, but the magnitude of that effect as a standalone agent appears to be modest — not the dramatic fat loss that the animal data initially suggested. In combination protocols with GH secretagogues, it may add a complementary lipolytic component without the insulin resistance concerns of full GH stimulation.
Reported Benefits
1. Fat-Specific Lipolysis Without Insulin Effects
The most practically important property of AOD-9604 for anyone combining it with other metabolic peptides: it targets fat breakdown through GH's lipolytic pathway without producing the insulin resistance and glucose elevation that accompany full GH secretagogue use. This makes it theoretically well-suited as an addition to GH secretagogue protocols in individuals with metabolic sensitivity to glucose.
2. No IGF-1 Elevation
For users who want to limit IGF-1 exposure — whether due to cancer history concerns or long-term safety considerations around sustained IGF-1 elevation — AOD-9604 offers a way to access some of GH's fat metabolism effects without driving IGF-1 upward.
3. Body Composition Support
In the context of a hypocaloric diet and training protocol, AOD-9604 may provide modest additional support for fat mobilization — particularly from subcutaneous fat depots — without the anabolic or hormonal effects that complicate full GH or GH secretagogue use in some contexts.
4. Cartilage and Joint Health (Emerging Evidence)
An unexpected area of research interest: preclinical studies have examined AOD-9604 for cartilage regeneration and repair, finding that it may promote chondrocyte activity through mechanisms distinct from its lipolytic pathway. This has generated interest in its potential role in osteoarthritis, though human data in this area is very limited. (View related studies on PubMed)
Dosage and Protocol
The following reflects the clinical trial doses and commonly discussed research protocols. This is not medical advice.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous injection | 200–300 mcg | Once daily, fasted (morning) | Most common research protocol; fasted state maximizes lipolytic effect |
| Oral | 1 mg/day | Once daily, fasted | Dose used in Phase 2 trials; oral bioavailability is low but was used in clinical research |
Timing note: Like GH secretagogues, AOD-9604's lipolytic effects are best accessed in a fasted state. Elevated insulin levels from recent food intake suppress fat cell responsiveness to lipolytic signals. Morning administration before eating or pre-workout in a fasted state is the standard approach in research protocols.
Common Stacks
| Stack Partner | Rationale |
|---|---|
| CJC-1295 w/o DAC + Ipamorelin | GH secretagogue stack drives GH/IGF-1 elevation for recovery and body composition; AOD-9604 adds targeted lipolytic activity without compounding glucose or IGF-1 burden |
| Fragment 176-191 | Both target the same fat-burning fragment region of GH; sometimes combined for additive lipolytic effect, though overlap in mechanism means synergy is not established |
| Tesamorelin | Tesamorelin is the most potent GHRH for visceral fat; AOD-9604 may complement by targeting subcutaneous fat depots through a different mechanism |
Side Effects and Safety
AOD-9604 has one of the cleanest safety profiles of any compound in this series — the extensive clinical trial program, including Phase 3, consistently found it well tolerated.
From Clinical Trials
- No significant adverse events attributable to AOD-9604 were identified in Phase 2 or Phase 3 trials
- No effects on fasting glucose, insulin resistance, or HbA1c
- No effects on IGF-1 levels
- No effects on thyroid function, cortisol, or other hormonal markers
- Injection site reactions — mild and transient, as with most subcutaneous peptides
Research Community Reports
- Mild facial flushing shortly after injection reported by some users
- Occasional mild headache, particularly in the first days of use
- Rare reports of nausea at higher doses
Important Note on Malignancy
Unlike full GH or GH secretagogues, AOD-9604 does not raise IGF-1 — removing one of the primary theoretical oncological concerns with GH-related peptides. The fragment has also shown no mitogenic (cell growth promoting) activity in research. The malignancy caution that applies to full GH protocols is less applicable here, though use with a cancer history should always involve physician oversight.
How to Reconstitute AOD-9604
- Use bacteriostatic water for reconstitution of injectable AOD-9604.
- Inject bacteriostatic water slowly into the vial along the inside wall — do not inject directly onto the powder.
- Gently swirl until fully dissolved. Do not shake.
- Store reconstituted vials in the refrigerator (2–8°C). Do not freeze after reconstitution.
- Reconstituted AOD-9604 is typically stable for 4–6 weeks under refrigeration.
Frequently Asked Questions
Did AOD-9604 fail in clinical trials?
Its Phase 3 trial did not demonstrate the statistically significant weight loss needed for FDA approval as an obesity drug. This is a meaningful clinical finding that should inform expectations. It does not mean the peptide has zero biological activity — its preclinical mechanism is sound and its safety profile is excellent — but it does mean that the fat loss magnitude it produces as a standalone agent in humans is modest, not dramatic.
Is AOD-9604 the same as Fragment 176-191?
They are closely related but not identical. Fragment 176-191 refers to amino acids 176–191 of the GH sequence without modification. AOD-9604 adds a tyrosine residue at position 177 for stability. In practical terms they are often used interchangeably in community discussions, but they are technically distinct compounds. The next post in this series covers Fragment 176-191 specifically.
Does AOD-9604 affect muscle mass?
No. Without IGF-1 stimulation or anabolic GH axis activation, AOD-9604 has no documented effect on muscle protein synthesis or muscle mass — in either direction. It targets fat metabolism specifically and does not carry the anabolic or catabolic effects of full GH administration.
Is AOD-9604 worth using for fat loss?
With realistic expectations — yes, potentially, as one component of a broader protocol. With the expectation of significant standalone fat loss comparable to GLP-1 agonists or even full GH therapy — no, the Phase 3 data does not support that. Its primary value in current research protocols is as a metabolically clean addition to GH secretagogue stacks for individuals who want fat-targeted GH fragment activity without IGF-1 or glucose concerns.
Why is AOD-9604 still popular if it failed Phase 3?
Several reasons: its safety profile is genuinely excellent, its GRAS designation provides regulatory credibility around safety, its mechanism is biologically sound even if the clinical magnitude was modest, and the peptide research community often uses compounds in stack combinations that were not evaluated in the standalone clinical trials. The Phase 3 trial tested it alone — community use typically combines it with other compounds.
Where to Learn More
- AOD-9604 research on PubMed
- Growth hormone fragment lipolysis research on PubMed
- FDA GRAS Notice for AOD-9604 (PDF)
For research-based posts on every major fat loss and metabolic peptide — from GH fragments and GLP-1 agonists to Fragment 176-191, 5-Amino-1MQ, and beyond — visit our resource library.
The Bottom Line
AOD-9604 is a peptide whose story is more instructive than its clinical outcome might suggest. It represents an intellectually honest attempt to engineer GH's fat-burning mechanism without its metabolic side effects — and that attempt largely succeeded at the mechanistic and safety level. Where it fell short was in producing clinically meaningful fat loss at the scale required for regulatory approval as a standalone drug.
That is a useful data point. It suggests that the lipolytic activity of the GH C-terminal fragment, while real, is not a dominant driver of fat loss at achievable peptide doses in humans — at least not when used alone. Whether it contributes meaningfully as one component of a multi-peptide protocol remains an open question that clinical trials have not addressed.
The next post covers Fragment 176-191 — AOD-9604's close structural relative, the unmodified GH fragment that targets the same lipolytic pathway with slightly different characteristics. Stay tuned.
No comments:
Post a Comment